Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
Research Spotlight
  • Allogeneic HCT should be considered as first-line treatment for SAA

    September 2018

  • Consensus Statement on HCT Late Effects Screening Guidelines in Hemoglobinopathies

    June 2018

  • HCT Can Be an Effective Treatment for Young Adults with Immune Deficiencies

    April 2018

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Severe Aplastic Anemia & Marrow Failure
  • Email
  • Print This Page

Related Resources

  • HCT Guidelines App
  • Subscribe to the Latest Research
  • ALL Outcomes and Trends Data

Patient Resources

  • Transplant and Severe Aplastic Anemia
  • Understanding Transplant Outcomes
  • Transplant Basics Booklet
  • Transplant Basics Videos

Severe Aplastic Anemia and Other Marrow Failure Syndromes

Bone marrow failure syndromes are a class of rare diseases with abnormal or absent hematopoeisis in one or more cell lines, and include acquired or congenital aplastic anemia, Fanconi anemia, and Diamond-Blackfan anemia. Most patients are diagnosed in childhood, mainly by presenting with hematologic findings such as single-cell or pancytopenia, myelodysplastic syndromes, or leukemia, particularly acute myeloid leukemia. [1]

Acquired aplastic anemia is thought to have an autoimmune component in many patients, and immunosuppressive therapy is therefore a typical front-line therapy. Patients with aplastic anemia are classified based on the severity of their marrow aplasia, and those with severe aplastic anemia (SAA) are candidates for allogeneic hematopoietic cell transplantation (HCT). [1-3]

Diamond-Blackfan anemia and Fanconi anemia are rare, genetically and clinically heterogeneous disorders, characterized by red cell aplasia. Many patients eventually develop pancytopenias from these syndromes. Allogeneic HCT offers the only potential cure for both disorders. [1,4] A 2016 study of long-term survival in patients transplanted for Fanconi anemia found that 10- and 15-year probabilities of survival were 90% and 79%, respectively. [5]

Advances

 

Clinical advances improving the outcomes of allogeneic transplants in patients with bone marrow failure syndromes include:

  • Using reduced-intensity fludarabine-based preparative regimens and drastically reducing or eliminating radiotherapy conditioning improves outcomes in Fanconi anemia patients, who are sensitive to DNA damage [1,6]
  • Using bone marrow rather than peripheral blood stem cells (PBSCs) in allogeneic HCT for SAA leads to significantly better outcomes [7,8]
  • Frontline alternative donor HCT may be a better treatment option than immunosupressive therapy for children and adolescents with SAA who lack an HLA-matched related donor [9]
  • Using unrelated donor HCT for Diamond-Blackfan anemia at the onset of bi- or trilineage cytopenia and/or the evolution to myelodysplasia or acute myelogenous leukemia [10]
 

Outcomes

 

Improved survival

Review outcomes for allogeneic transplantation in patients with bone marrow failure syndromes below. View additional SAA Outcome slides showing demographic data and transplant trends.

Outcome data in this section have been prepared by the Center for International Blood and Marrow Transplant Research® (CIBMTR®), our research program.

As shown in Figures 1 and 2, survival is significantly better at two years post-transplant for both adult and pediatric patients with SAA transplanted during later time periods compared to patients transplanted during earlier time periods (log-rank p-value <0.001).

Figure 1: Adult Severe Aplastic Anemia Survival Over Time, Unrelated HCT

Adult Severe Aplastic Anemia Survival Over Time, Unrelated HCT

Download slide "Adult Severe Aplastic Anemia Survival Over Time, Unrelated HCT"

Figure 2: Pediatric Severe Aplastic Anemia Survival Over Time, Unrelated HCT

Pediatric Severe Aplastic Anemia Survival Over Time, Unrelated HCT

Download slide "Pediatric Severe Aplastic Anemia Survival Over Time, Unrelated HCT"

Figure 3: Severe Aplastic Anemia Survival, Unrelated HCT, by Age

Severe Aplastic Anemia Survival, Unrelated Marrow HCT, by Age

Download slide "Severe Aplastic Anemia Survival, Unrelated Marrow HCT, by Age"

Figure 4: Pediatric Fanconi Anemia Survival, Unrelated HCT, by Cell Source

Pediatric Fanconi Anemia Survival, Unrelated HCT, by Cell Source

Download slide "Pediatric Fanconi Anemia Survival, Unrelated HCT, by Cell Source"

Figure 5: Severe Aplastic Anemia Survival, Allogeneic HCT in Adults, by Donor Type

Severe Aplastic Anemia Survival, Allogeneic HCT in Adults, by Donor Type

Download slide "Severe Aplastic Anemia Survival, Allogeneic HCT in Adults, by Donor Type"

Figure 6: Severe Aplastic Anemia Survival, Allogeneic HCT in Pediatric Patients, by Donor Type

Severe Aplastic Anemia Survival, Allogeneic HCT in Pediatric Patients, by Donor Type

Download slide "Severe Aplastic Anemia Survival, Allogeneic HCT in Pediatric Patients, by Donor Type"

Referral Timing Guidelines

 

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for transplantation. [11]

Transplant Consultation Guidelines: Severe Aplastic Anemia and Other Marrow Failure Syndromes

(including Fanconi anemia, Diamond-Blackfan anemia, Shwachman-Diamond syndrome and others)

  • At diagnosis

Download as slides (PPT)
View complete Referral Timing Guidelines

References

  1. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017; 130(21): 2257-2264. Access
  2. Tolar J, Sodani P, Symons H. Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant. 2015; 50(5): 619-627. Access
  3. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012; 120(6): 1185-1196. Access  
  4. Smith AR, Wagner JE. Current clinical management of Fanconi anemia. Expert Rev Hematol. 2012; 5(5): 513-522. Access
  5. Bonfim C, Ribeiro L, Nichele S, et al. Long-term survival, organ function, and malignancy after hematopoietic stem cell transplantation for Fanconi anemia. Biol Blood Marrow Transplant. 2016; 22(7): 1257-1263. Access
  6. de Latour RP, Porcher R, Dalle J-H, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2013; 122(26): 4279-4286. Access
  7. Chu R, Brazauskas R, Kan F, et al. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011; 17(7): 1018-1024. Access  
  8. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011; 118(9): 2618-2621. Access
  9. Choi YB, Yi ES, Lee JW, et al. Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor. Bone Marrow Transplant. 2017; 52(1): 47-52. Access
  10. Narla A, Vlachos A, Nathan DG. Diamond Blackfan anemia treatment: Past, present, and future. Semin Hematol. 2011; 48(2): 117-123. Access
  11. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2021 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright